DARE - Company ID 0001401914
The table below shows Dare Bioscience, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.89M | $5.47M | -$38.86M | -$18.09M | -$28.76M | -$25.23M |
| Capital expenditure | $385.28K | $573.05K | $629.43K | $63.07K | $14.52K | $17.63K |
| Investing cash flow | -$385.28K | -$573.05K | -$629.43K | -$63.07K | -$14.52K | -$17.63K |
| Dividends paid | - | - | - | - |
Dare Bioscience, Inc. reported operating cash flow of -$9.89M for fiscal year 2025. That is down 280.6% from $5.47M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$2.54M (FY 2017) to -$9.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $19.28M | $354.52K | $15.64M | $1.34M | $75.85M | $25.13M |